Publications for Arthur J. L. Cooper arthur_cooper@nymc.edu

Bemeur, C., Cudalbu, C., Dam, G., Thrane, A. S., Cooper, A. J., & Rose, C. F. (2016). Brain edema: A valid endpoint for measuring hepatic encephalopathy? Metabolic Brain Disease, 31(6), 1249-1258. doi:10.1007/s11011-016-9843-9

Cooper, A. J., & Jeitner, T. M. (2016). Central role of glutamate metabolism in the maintenance of nitrogen homeostasis in normal and hyperammonemic brain. Biomolecules, 6(2), 16. doi:10.3390/biom6020016

Cooper, A. J., Shurubor, Y. I., Dorai, T., Pinto, J. T., Isakova, E. P., Deryabina, Y. I., . . . Krasnikov, B. F. (2016). Omega-amidase: An underappreciated, but important enzyme in L-glutamine and L-asparagine metabolism; relevance to sulfur and nitrogen metabolism, tumor biology and hyperammonemic diseases. Amino Acids, 48(1), 1-20. doi:10.1007/s00726-015-2061-7

Dorai, T., Pinto, J. T., & Cooper, A. J. (2016). Sweetening of glutamine metabolism in cancer cells by Rho GTPases through convergence of multiple oncogenic signaling pathways. Translational Cancer Research, 5(S2), S349-S356. doi:10.21037/tcr.2016.07.43

Jeitner, T. M., Kristoferson, E., Azcona, J. A., Pinto, J. T., Stalnecker, C., Erickson, J. W., . . . Cooper, A. J. L. (2016). Fluorination at the 4 position alters the substrate behavior of l-glutamine and l-glutamate: Implications for positron emission tomography of neoplasias. Journal of Fluorine Chemistry, 192(Part A), 58-67. doi:10.1016/j.jfluchem.2016.10.008

Lerma-Ortiz, C., Jeffryes, J. G., Cooper, A. J., Niehaus, T. D., Thamm, A. M., Frelin, O., . . . Hanson, A. D. (2016). 'Nothing of chemistry disappears in biology': The Top 30 damage-prone endogenous metabolites. Biochemical Society Transactions, 44(3), 961-971. doi:10.1042/BST20160073

Lin, C. H., Chen, J., Zhang, Z., Johnson, G. V., Cooper, A. J., Feola, J., . . . Goligorsky, M. S. (2016). Endostatin and transglutaminase 2 are involved in fibrosis of the aging kidney. Kidney International, 89(6), 1281-1292. doi:10.1016/j.kint.2016.01.030

Cooper, A. J. (2015). Intracranial glioblastomas: New hope for an effective treatment. Ebiomedicine, 2, 1016-1017. doi:10.1016/j.ebiom.2015.08.029

Cooper, A. J., Shurubor, Y. I., Dorai, T., Pinto, J. T., Isakova, E. P., Deryabina, Y. I., . . . Krasnikov, B. F. (2015). Erratum to: Omega-amidase: An underappreciated, but important enzyme in L-glutamine and L-asparagine metabolism; relevance to sulfur and nitrogen metabolism, tumor biology and hyperammonemic diseases. Amino Acids, 47(12), 2671-2672. doi:10.1007/s00726-015-2115-x

Hallen, A., & Cooper, A. J. (2015). Letter to the editor: Mu-crystallin/CRYM functions as a ketimine-reducing enzyme and plays a role in thyroid hormone bioavailability due to strong inhibition/regulation by thyroid hormones. The Journal of Clinical Endocrinology and Metabolism, 100(1), L15-L16. doi:10.1210/jc.2014-3963

Hallen, A., Cooper, A. J., Jamie, J. F., & Karuso, P. (2015). Insights into enzyme catalysis and thyroid hormone regulation of cerebral ketimine reductase/mu-crystallin under physiological conditions. Neurochemical Research, 40(6), 1252-1266. doi:10.1007/s11064-015-1590-5

Hallen, A., Cooper, A. +., Smith, J. R., Jamie, J. F., & Karuso, P. (2015). Ketimine reductase/CRYM catalyzes reductive alkylamination of alpha-keto acids, confirming its function as an imine reductase. Amino Acids, 47(11), 2457-2461. doi:10.1007/s00726-015-2044-8

Jeitner, T. M., Battaile, K., & Cooper, A. J. (2015). Critical evaluation of the changes in glutamine synthetase activity in models of cerebral stroke. Neurochemical Research, 40(12), 2544-2556. doi:10.1007/s11064-015-1667-1

Cooper, A. J., & Kuhara, T. (2014). alpha-Ketoglutaramate: an overlooked metabolite of glutamine and a biomarker for hepatic encephalopathy and inborn errors of the urea cycle. Metabolic Brain Disease, 29(4), 991-1006. doi:10.1007/s11011-013-9444-9

Hallen, A., Jamie, J. F., & Cooper, A. J. (2014). Imine reductases: A comparison of glutamate dehydrogenase to ketimine reductases in the brain. Neurochemical Research, 39(3), 527-541. doi:10.1007/s11064-012-0964-1

Hallen, A., Jamie, J. F., & Cooper, A. J. L. (2014). Imine reductases: A comparison of glutamate dehydrogenase to ketimine reductases in the brain. Neurochemical Research, 39(3), 527-541. doi:10.1007/s11064-012-0964-1

Jeitner, T. M., & Cooper, A. J. (2014). Inhibition of human glutamine synthetase by L-methionine-S,R-sulfoximine-relevance to the treatment of neurological diseases. Metabolic Brain Disease, 29(4), 983-989. doi:10.1007/s11011-013-9439-6

Niehaus, T. D., Nguyen, T. N., Gidda, S. K., ElBadawi-Sidhu, M., Lambrecht, J. A., McCarty, D. R., . . . Cooper, A. J. L. (2014). Arabidopsis and maize RidA proteins preempt reactive Enamine/Imine damage to branched-chain amino acid biosynthesis in plastids. The Plant Cell, 26(7), 3010-3022. doi:10.1105/tpc.114.126854

Pinto, J. T. , & Cooper, A. J. (2014). From cholesterogenesis to steroidogenesis: Role of riboflavin and flavoenzymes in the biosynthesis of vitamin D. Advances in Nutrition, 5(2), 144-163. doi:10.3945/an.113.00518

Pinto, J. T., Krasnikov, B. F., Alcutt, S., Jones, M. E., Dorai, T., Villar, M. T., . . . Cooper, A. J. (2014). Kynurenine aminotransferase III and glutamine transaminase L are identical enzymes that have cysteine S-conjugate beta-lyase activity and can transaminate L-selenomethionine. The Journal of Biological Chemistry, 289(45), 30950-30961. doi:10.1074/jbc.M114.591461

Toohey, J. I., & Cooper, A. J. (2014). Thiosulfoxide (sulfane) sulfur: New chemistry and new regulatory roles in biology. Molecules, 19(8), 12789-12813.

Toohey, J. I., & Cooper, A. J. (2014). Thiosulfoxide (sulfane) sulfur: New chemistry and new regulatory roles in biology. Molecules, 19(8), 12789-12813. doi:10.3390/molecules190812789

Townsend, D. M., Lushchak, V. I., & Cooper, A. J. (2014). A comparison of reversible versus irreversible protein glutathionylation. Advances in Cancer Research, 122, 177-198. doi:10.1016/B978-0-12-420117-0.00005-0

Vauzour, D., Pinto, J. T., Cooper, A. J., & Spencer, J. P. (2014). The neurotoxicity of 5-S-cysteinyldopamine is mediated by the early activation of ERK1/2 followed by the subsequent activation of ASK1/JNK1/2 pro-apoptotic signalling. The Biochemical Journal, 463(1), 41-52. doi:10.1042/BJ20131519

Cooper, A. J. L. (2013). Possible treatment of end-stage hyperammonemic encephalopathy by inhibition of glutamine synthetase. Metabolic Brain Disease, 28(2), 119-125. doi:10.1007/s11011-012-9338-2